Global Peptide CDMO Pharmaceutical Supply, Demand and Key Producers, 2023-2029

Page: 127

Published Date: 29 Mar 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags

Description

The global Peptide CDMO Pharmaceutical market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Peptide CDMO Pharmaceutical demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Peptide CDMO Pharmaceutical, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peptide CDMO Pharmaceutical that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Peptide CDMO Pharmaceutical total market, 2018-2029, (USD Million)
Global Peptide CDMO Pharmaceutical total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Peptide CDMO Pharmaceutical total market, key domestic companies and share, (USD Million)
Global Peptide CDMO Pharmaceutical revenue by player and market share 2018-2023, (USD Million)
Global Peptide CDMO Pharmaceutical total market by Type, CAGR, 2018-2029, (USD Million)
Global Peptide CDMO Pharmaceutical total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Peptide CDMO Pharmaceutical market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Ambiopharm, Auspep, Bachem, Bcn Peptide, Cpc Scientific, Creative Peptides, Chinese Peptide, Csbio and Corden Pharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Peptide CDMO Pharmaceutical market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Peptide CDMO Pharmaceutical Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Peptide CDMO Pharmaceutical Market, Segmentation by Type
    Liquid-phase Peptide Synthesis（LPPS）
    Solid-phase Peptide Synthesis（SPPS）
    Mixed Phase

Global Peptide CDMO Pharmaceutical Market, Segmentation by Application
    Peptide Supplements
    Peptide Vaccines
    Others

Companies Profiled:
    Ambiopharm
    Auspep
    Bachem
    Bcn Peptide
    Cpc Scientific
    Creative Peptides
    Chinese Peptide
    Csbio
    Corden Pharma
    Polypeptide
    Hybio Pharmaceutical
    Peptide Institute
    Pepscan
    Almac
    Vivitide
    Creosalus Inc
    Scinopharm
    Senn Chemicals
    Belyntic
    Ferring Pharma
    Numaferm
    Hybio Pharmaceutical
    Provepharm Life Solutions
    Enzene Biosciences
    Piramal Pharma

Key Questions Answered
1. How big is the global Peptide CDMO Pharmaceutical market?
2. What is the demand of the global Peptide CDMO Pharmaceutical market?
3. What is the year over year growth of the global Peptide CDMO Pharmaceutical market?
4. What is the total value of the global Peptide CDMO Pharmaceutical market?
5. Who are the major players in the global Peptide CDMO Pharmaceutical market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Peptide CDMO Pharmaceutical Introduction
    1.2 World Peptide CDMO Pharmaceutical Market Size & Forecast (2018 & 2022 & 2029)
    1.3 World Peptide CDMO Pharmaceutical Total Market by Region (by Headquarter Location)
        1.3.1 World Peptide CDMO Pharmaceutical Market Size by Region (2018-2029), (by Headquarter Location)
        1.3.2 United States Peptide CDMO Pharmaceutical Market Size (2018-2029)
        1.3.3 China Peptide CDMO Pharmaceutical Market Size (2018-2029)
        1.3.4 Europe Peptide CDMO Pharmaceutical Market Size (2018-2029)
        1.3.5 Japan Peptide CDMO Pharmaceutical Market Size (2018-2029)
        1.3.6 South Korea Peptide CDMO Pharmaceutical Market Size (2018-2029)
        1.3.7 ASEAN Peptide CDMO Pharmaceutical Market Size (2018-2029)
        1.3.8 India Peptide CDMO Pharmaceutical Market Size (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Peptide CDMO Pharmaceutical Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Peptide CDMO Pharmaceutical Major Market Trends
    1.5 Influence of COVID-19 and Russia-Ukraine War
        1.5.1 Influence of COVID-19
        1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
    2.1 World Peptide CDMO Pharmaceutical Consumption Value (2018-2029)
    2.2 World Peptide CDMO Pharmaceutical Consumption Value by Region
        2.2.1 World Peptide CDMO Pharmaceutical Consumption Value by Region (2018-2023)
        2.2.2 World Peptide CDMO Pharmaceutical Consumption Value Forecast by Region (2024-2029)
    2.3 United States Peptide CDMO Pharmaceutical Consumption Value (2018-2029)
    2.4 China Peptide CDMO Pharmaceutical Consumption Value (2018-2029)
    2.5 Europe Peptide CDMO Pharmaceutical Consumption Value (2018-2029)
    2.6 Japan Peptide CDMO Pharmaceutical Consumption Value (2018-2029)
    2.7 South Korea Peptide CDMO Pharmaceutical Consumption Value (2018-2029)
    2.8 ASEAN Peptide CDMO Pharmaceutical Consumption Value (2018-2029)
    2.9 India Peptide CDMO Pharmaceutical Consumption Value (2018-2029)

3 World Peptide CDMO Pharmaceutical Companies Competitive Analysis
    3.1 World Peptide CDMO Pharmaceutical Revenue by Player (2018-2023)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Peptide CDMO Pharmaceutical Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Peptide CDMO Pharmaceutical in 2022
        3.2.3 Global Concentration Ratios (CR8) for Peptide CDMO Pharmaceutical in 2022
    3.3 Peptide CDMO Pharmaceutical Company Evaluation Quadrant
    3.4 Peptide CDMO Pharmaceutical Market: Overall Company Footprint Analysis
        3.4.1 Peptide CDMO Pharmaceutical Market: Region Footprint
        3.4.2 Peptide CDMO Pharmaceutical Market: Company Product Type Footprint
        3.4.3 Peptide CDMO Pharmaceutical Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Peptide CDMO Pharmaceutical Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Peptide CDMO Pharmaceutical Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
        4.1.2 United States VS China: Peptide CDMO Pharmaceutical Revenue Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States Based Companies VS China Based Companies: Peptide CDMO Pharmaceutical Consumption Value Comparison
        4.2.1 United States VS China: Peptide CDMO Pharmaceutical Consumption Value Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Peptide CDMO Pharmaceutical Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States Based Peptide CDMO Pharmaceutical Companies and Market Share, 2018-2023
        4.3.1 United States Based Peptide CDMO Pharmaceutical Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Peptide CDMO Pharmaceutical Revenue, (2018-2023)
    4.4 China Based Companies Peptide CDMO Pharmaceutical Revenue and Market Share, 2018-2023
        4.4.1 China Based Peptide CDMO Pharmaceutical Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Peptide CDMO Pharmaceutical Revenue, (2018-2023)
    4.5 Rest of World Based Peptide CDMO Pharmaceutical Companies and Market Share, 2018-2023
        4.5.1 Rest of World Based Peptide CDMO Pharmaceutical Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Peptide CDMO Pharmaceutical Revenue, (2018-2023)

5 Market Analysis by Type
    5.1 World Peptide CDMO Pharmaceutical Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Liquid-phase Peptide Synthesis（LPPS）
        5.2.2 Solid-phase Peptide Synthesis（SPPS）
        5.2.3 Mixed Phase
    5.3 Market Segment by Type
        5.3.1 World Peptide CDMO Pharmaceutical Market Size by Type (2018-2023)
        5.3.2 World Peptide CDMO Pharmaceutical Market Size by Type (2024-2029)
        5.3.3 World Peptide CDMO Pharmaceutical Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Peptide CDMO Pharmaceutical Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Peptide Supplements
        6.2.2 Peptide Vaccines
        6.2.3 Others
    6.3 Market Segment by Application
        6.3.1 World Peptide CDMO Pharmaceutical Market Size by Application (2018-2023)
        6.3.2 World Peptide CDMO Pharmaceutical Market Size by Application (2024-2029)
        6.3.3 World Peptide CDMO Pharmaceutical Market Size by Application (2018-2029)

7 Company Profiles
    7.1 Ambiopharm
        7.1.1 Ambiopharm Details
        7.1.2 Ambiopharm Major Business
        7.1.3 Ambiopharm Peptide CDMO Pharmaceutical Product and Services
        7.1.4 Ambiopharm Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.1.5 Ambiopharm Recent Developments/Updates
        7.1.6 Ambiopharm Competitive Strengths & Weaknesses
    7.2 Auspep
        7.2.1 Auspep Details
        7.2.2 Auspep Major Business
        7.2.3 Auspep Peptide CDMO Pharmaceutical Product and Services
        7.2.4 Auspep Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.2.5 Auspep Recent Developments/Updates
        7.2.6 Auspep Competitive Strengths & Weaknesses
    7.3 Bachem
        7.3.1 Bachem Details
        7.3.2 Bachem Major Business
        7.3.3 Bachem Peptide CDMO Pharmaceutical Product and Services
        7.3.4 Bachem Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.3.5 Bachem Recent Developments/Updates
        7.3.6 Bachem Competitive Strengths & Weaknesses
    7.4 Bcn Peptide
        7.4.1 Bcn Peptide Details
        7.4.2 Bcn Peptide Major Business
        7.4.3 Bcn Peptide Peptide CDMO Pharmaceutical Product and Services
        7.4.4 Bcn Peptide Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.4.5 Bcn Peptide Recent Developments/Updates
        7.4.6 Bcn Peptide Competitive Strengths & Weaknesses
    7.5 Cpc Scientific
        7.5.1 Cpc Scientific Details
        7.5.2 Cpc Scientific Major Business
        7.5.3 Cpc Scientific Peptide CDMO Pharmaceutical Product and Services
        7.5.4 Cpc Scientific Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.5.5 Cpc Scientific Recent Developments/Updates
        7.5.6 Cpc Scientific Competitive Strengths & Weaknesses
    7.6 Creative Peptides
        7.6.1 Creative Peptides Details
        7.6.2 Creative Peptides Major Business
        7.6.3 Creative Peptides Peptide CDMO Pharmaceutical Product and Services
        7.6.4 Creative Peptides Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.6.5 Creative Peptides Recent Developments/Updates
        7.6.6 Creative Peptides Competitive Strengths & Weaknesses
    7.7 Chinese Peptide
        7.7.1 Chinese Peptide Details
        7.7.2 Chinese Peptide Major Business
        7.7.3 Chinese Peptide Peptide CDMO Pharmaceutical Product and Services
        7.7.4 Chinese Peptide Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.7.5 Chinese Peptide Recent Developments/Updates
        7.7.6 Chinese Peptide Competitive Strengths & Weaknesses
    7.8 Csbio
        7.8.1 Csbio Details
        7.8.2 Csbio Major Business
        7.8.3 Csbio Peptide CDMO Pharmaceutical Product and Services
        7.8.4 Csbio Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.8.5 Csbio Recent Developments/Updates
        7.8.6 Csbio Competitive Strengths & Weaknesses
    7.9 Corden Pharma
        7.9.1 Corden Pharma Details
        7.9.2 Corden Pharma Major Business
        7.9.3 Corden Pharma Peptide CDMO Pharmaceutical Product and Services
        7.9.4 Corden Pharma Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.9.5 Corden Pharma Recent Developments/Updates
        7.9.6 Corden Pharma Competitive Strengths & Weaknesses
    7.10 Polypeptide
        7.10.1 Polypeptide Details
        7.10.2 Polypeptide Major Business
        7.10.3 Polypeptide Peptide CDMO Pharmaceutical Product and Services
        7.10.4 Polypeptide Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.10.5 Polypeptide Recent Developments/Updates
        7.10.6 Polypeptide Competitive Strengths & Weaknesses
    7.11 Hybio Pharmaceutical
        7.11.1 Hybio Pharmaceutical Details
        7.11.2 Hybio Pharmaceutical Major Business
        7.11.3 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Product and Services
        7.11.4 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.11.5 Hybio Pharmaceutical Recent Developments/Updates
        7.11.6 Hybio Pharmaceutical Competitive Strengths & Weaknesses
    7.12 Peptide Institute
        7.12.1 Peptide Institute Details
        7.12.2 Peptide Institute Major Business
        7.12.3 Peptide Institute Peptide CDMO Pharmaceutical Product and Services
        7.12.4 Peptide Institute Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.12.5 Peptide Institute Recent Developments/Updates
        7.12.6 Peptide Institute Competitive Strengths & Weaknesses
    7.13 Pepscan
        7.13.1 Pepscan Details
        7.13.2 Pepscan Major Business
        7.13.3 Pepscan Peptide CDMO Pharmaceutical Product and Services
        7.13.4 Pepscan Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.13.5 Pepscan Recent Developments/Updates
        7.13.6 Pepscan Competitive Strengths & Weaknesses
    7.14 Almac
        7.14.1 Almac Details
        7.14.2 Almac Major Business
        7.14.3 Almac Peptide CDMO Pharmaceutical Product and Services
        7.14.4 Almac Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.14.5 Almac Recent Developments/Updates
        7.14.6 Almac Competitive Strengths & Weaknesses
    7.15 Vivitide
        7.15.1 Vivitide Details
        7.15.2 Vivitide Major Business
        7.15.3 Vivitide Peptide CDMO Pharmaceutical Product and Services
        7.15.4 Vivitide Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.15.5 Vivitide Recent Developments/Updates
        7.15.6 Vivitide Competitive Strengths & Weaknesses
    7.16 Creosalus Inc
        7.16.1 Creosalus Inc Details
        7.16.2 Creosalus Inc Major Business
        7.16.3 Creosalus Inc Peptide CDMO Pharmaceutical Product and Services
        7.16.4 Creosalus Inc Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.16.5 Creosalus Inc Recent Developments/Updates
        7.16.6 Creosalus Inc Competitive Strengths & Weaknesses
    7.17 Scinopharm
        7.17.1 Scinopharm Details
        7.17.2 Scinopharm Major Business
        7.17.3 Scinopharm Peptide CDMO Pharmaceutical Product and Services
        7.17.4 Scinopharm Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.17.5 Scinopharm Recent Developments/Updates
        7.17.6 Scinopharm Competitive Strengths & Weaknesses
    7.18 Senn Chemicals
        7.18.1 Senn Chemicals Details
        7.18.2 Senn Chemicals Major Business
        7.18.3 Senn Chemicals Peptide CDMO Pharmaceutical Product and Services
        7.18.4 Senn Chemicals Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.18.5 Senn Chemicals Recent Developments/Updates
        7.18.6 Senn Chemicals Competitive Strengths & Weaknesses
    7.19 Belyntic
        7.19.1 Belyntic Details
        7.19.2 Belyntic Major Business
        7.19.3 Belyntic Peptide CDMO Pharmaceutical Product and Services
        7.19.4 Belyntic Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.19.5 Belyntic Recent Developments/Updates
        7.19.6 Belyntic Competitive Strengths & Weaknesses
    7.20 Ferring Pharma
        7.20.1 Ferring Pharma Details
        7.20.2 Ferring Pharma Major Business
        7.20.3 Ferring Pharma Peptide CDMO Pharmaceutical Product and Services
        7.20.4 Ferring Pharma Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.20.5 Ferring Pharma Recent Developments/Updates
        7.20.6 Ferring Pharma Competitive Strengths & Weaknesses
    7.21 Numaferm
        7.21.1 Numaferm Details
        7.21.2 Numaferm Major Business
        7.21.3 Numaferm Peptide CDMO Pharmaceutical Product and Services
        7.21.4 Numaferm Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.21.5 Numaferm Recent Developments/Updates
        7.21.6 Numaferm Competitive Strengths & Weaknesses
    7.22 Hybio Pharmaceutical
        7.22.1 Hybio Pharmaceutical Details
        7.22.2 Hybio Pharmaceutical Major Business
        7.22.3 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Product and Services
        7.22.4 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.22.5 Hybio Pharmaceutical Recent Developments/Updates
        7.22.6 Hybio Pharmaceutical Competitive Strengths & Weaknesses
    7.23 Provepharm Life Solutions
        7.23.1 Provepharm Life Solutions Details
        7.23.2 Provepharm Life Solutions Major Business
        7.23.3 Provepharm Life Solutions Peptide CDMO Pharmaceutical Product and Services
        7.23.4 Provepharm Life Solutions Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.23.5 Provepharm Life Solutions Recent Developments/Updates
        7.23.6 Provepharm Life Solutions Competitive Strengths & Weaknesses
    7.24 Enzene Biosciences
        7.24.1 Enzene Biosciences Details
        7.24.2 Enzene Biosciences Major Business
        7.24.3 Enzene Biosciences Peptide CDMO Pharmaceutical Product and Services
        7.24.4 Enzene Biosciences Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.24.5 Enzene Biosciences Recent Developments/Updates
        7.24.6 Enzene Biosciences Competitive Strengths & Weaknesses
    7.25 Piramal Pharma
        7.25.1 Piramal Pharma Details
        7.25.2 Piramal Pharma Major Business
        7.25.3 Piramal Pharma Peptide CDMO Pharmaceutical Product and Services
        7.25.4 Piramal Pharma Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023)
        7.25.5 Piramal Pharma Recent Developments/Updates
        7.25.6 Piramal Pharma Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Peptide CDMO Pharmaceutical Industry Chain
    8.2 Peptide CDMO Pharmaceutical Upstream Analysis
    8.3 Peptide CDMO Pharmaceutical Midstream Analysis
    8.4 Peptide CDMO Pharmaceutical Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Peptide CDMO Pharmaceutical Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
    Table 2. World Peptide CDMO Pharmaceutical Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
    Table 3. World Peptide CDMO Pharmaceutical Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
    Table 4. World Peptide CDMO Pharmaceutical Revenue Market Share by Region (2018-2023), (by Headquarter Location)
    Table 5. World Peptide CDMO Pharmaceutical Revenue Market Share by Region (2024-2029), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Peptide CDMO Pharmaceutical Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
    Table 8. World Peptide CDMO Pharmaceutical Consumption Value by Region (2018-2023) & (USD Million)
    Table 9. World Peptide CDMO Pharmaceutical Consumption Value Forecast by Region (2024-2029) & (USD Million)
    Table 10. World Peptide CDMO Pharmaceutical Revenue by Player (2018-2023) & (USD Million)
    Table 11. Revenue Market Share of Key Peptide CDMO Pharmaceutical Players in 2022
    Table 12. World Peptide CDMO Pharmaceutical Industry Rank of Major Player, Based on Revenue in 2022
    Table 13. Global Peptide CDMO Pharmaceutical Company Evaluation Quadrant
    Table 14. Head Office of Key Peptide CDMO Pharmaceutical Player
    Table 15. Peptide CDMO Pharmaceutical Market: Company Product Type Footprint
    Table 16. Peptide CDMO Pharmaceutical Market: Company Product Application Footprint
    Table 17. Peptide CDMO Pharmaceutical Mergers & Acquisitions Activity
    Table 18. United States VS China Peptide CDMO Pharmaceutical Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 19. United States VS China Peptide CDMO Pharmaceutical Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 20. United States Based Peptide CDMO Pharmaceutical Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Peptide CDMO Pharmaceutical Revenue, (2018-2023) & (USD Million)
    Table 22. United States Based Companies Peptide CDMO Pharmaceutical Revenue Market Share (2018-2023)
    Table 23. China Based Peptide CDMO Pharmaceutical Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Peptide CDMO Pharmaceutical Revenue, (2018-2023) & (USD Million)
    Table 25. China Based Companies Peptide CDMO Pharmaceutical Revenue Market Share (2018-2023)
    Table 26. Rest of World Based Peptide CDMO Pharmaceutical Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Peptide CDMO Pharmaceutical Revenue, (2018-2023) & (USD Million)
    Table 28. Rest of World Based Companies Peptide CDMO Pharmaceutical Revenue Market Share (2018-2023)
    Table 29. World Peptide CDMO Pharmaceutical Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Table 30. World Peptide CDMO Pharmaceutical Market Size by Type (2018-2023) & (USD Million)
    Table 31. World Peptide CDMO Pharmaceutical Market Size by Type (2024-2029) & (USD Million)
    Table 32. World Peptide CDMO Pharmaceutical Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Table 33. World Peptide CDMO Pharmaceutical Market Size by Application (2018-2023) & (USD Million)
    Table 34. World Peptide CDMO Pharmaceutical Market Size by Application (2024-2029) & (USD Million)
    Table 35. Ambiopharm Basic Information, Area Served and Competitors
    Table 36. Ambiopharm Major Business
    Table 37. Ambiopharm Peptide CDMO Pharmaceutical Product and Services
    Table 38. Ambiopharm Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 39. Ambiopharm Recent Developments/Updates
    Table 40. Ambiopharm Competitive Strengths & Weaknesses
    Table 41. Auspep Basic Information, Area Served and Competitors
    Table 42. Auspep Major Business
    Table 43. Auspep Peptide CDMO Pharmaceutical Product and Services
    Table 44. Auspep Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 45. Auspep Recent Developments/Updates
    Table 46. Auspep Competitive Strengths & Weaknesses
    Table 47. Bachem Basic Information, Area Served and Competitors
    Table 48. Bachem Major Business
    Table 49. Bachem Peptide CDMO Pharmaceutical Product and Services
    Table 50. Bachem Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 51. Bachem Recent Developments/Updates
    Table 52. Bachem Competitive Strengths & Weaknesses
    Table 53. Bcn Peptide Basic Information, Area Served and Competitors
    Table 54. Bcn Peptide Major Business
    Table 55. Bcn Peptide Peptide CDMO Pharmaceutical Product and Services
    Table 56. Bcn Peptide Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 57. Bcn Peptide Recent Developments/Updates
    Table 58. Bcn Peptide Competitive Strengths & Weaknesses
    Table 59. Cpc Scientific Basic Information, Area Served and Competitors
    Table 60. Cpc Scientific Major Business
    Table 61. Cpc Scientific Peptide CDMO Pharmaceutical Product and Services
    Table 62. Cpc Scientific Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 63. Cpc Scientific Recent Developments/Updates
    Table 64. Cpc Scientific Competitive Strengths & Weaknesses
    Table 65. Creative Peptides Basic Information, Area Served and Competitors
    Table 66. Creative Peptides Major Business
    Table 67. Creative Peptides Peptide CDMO Pharmaceutical Product and Services
    Table 68. Creative Peptides Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 69. Creative Peptides Recent Developments/Updates
    Table 70. Creative Peptides Competitive Strengths & Weaknesses
    Table 71. Chinese Peptide Basic Information, Area Served and Competitors
    Table 72. Chinese Peptide Major Business
    Table 73. Chinese Peptide Peptide CDMO Pharmaceutical Product and Services
    Table 74. Chinese Peptide Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 75. Chinese Peptide Recent Developments/Updates
    Table 76. Chinese Peptide Competitive Strengths & Weaknesses
    Table 77. Csbio Basic Information, Area Served and Competitors
    Table 78. Csbio Major Business
    Table 79. Csbio Peptide CDMO Pharmaceutical Product and Services
    Table 80. Csbio Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 81. Csbio Recent Developments/Updates
    Table 82. Csbio Competitive Strengths & Weaknesses
    Table 83. Corden Pharma Basic Information, Area Served and Competitors
    Table 84. Corden Pharma Major Business
    Table 85. Corden Pharma Peptide CDMO Pharmaceutical Product and Services
    Table 86. Corden Pharma Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 87. Corden Pharma Recent Developments/Updates
    Table 88. Corden Pharma Competitive Strengths & Weaknesses
    Table 89. Polypeptide Basic Information, Area Served and Competitors
    Table 90. Polypeptide Major Business
    Table 91. Polypeptide Peptide CDMO Pharmaceutical Product and Services
    Table 92. Polypeptide Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 93. Polypeptide Recent Developments/Updates
    Table 94. Polypeptide Competitive Strengths & Weaknesses
    Table 95. Hybio Pharmaceutical Basic Information, Area Served and Competitors
    Table 96. Hybio Pharmaceutical Major Business
    Table 97. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Product and Services
    Table 98. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 99. Hybio Pharmaceutical Recent Developments/Updates
    Table 100. Hybio Pharmaceutical Competitive Strengths & Weaknesses
    Table 101. Peptide Institute Basic Information, Area Served and Competitors
    Table 102. Peptide Institute Major Business
    Table 103. Peptide Institute Peptide CDMO Pharmaceutical Product and Services
    Table 104. Peptide Institute Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 105. Peptide Institute Recent Developments/Updates
    Table 106. Peptide Institute Competitive Strengths & Weaknesses
    Table 107. Pepscan Basic Information, Area Served and Competitors
    Table 108. Pepscan Major Business
    Table 109. Pepscan Peptide CDMO Pharmaceutical Product and Services
    Table 110. Pepscan Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 111. Pepscan Recent Developments/Updates
    Table 112. Pepscan Competitive Strengths & Weaknesses
    Table 113. Almac Basic Information, Area Served and Competitors
    Table 114. Almac Major Business
    Table 115. Almac Peptide CDMO Pharmaceutical Product and Services
    Table 116. Almac Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 117. Almac Recent Developments/Updates
    Table 118. Almac Competitive Strengths & Weaknesses
    Table 119. Vivitide Basic Information, Area Served and Competitors
    Table 120. Vivitide Major Business
    Table 121. Vivitide Peptide CDMO Pharmaceutical Product and Services
    Table 122. Vivitide Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 123. Vivitide Recent Developments/Updates
    Table 124. Vivitide Competitive Strengths & Weaknesses
    Table 125. Creosalus Inc Basic Information, Area Served and Competitors
    Table 126. Creosalus Inc Major Business
    Table 127. Creosalus Inc Peptide CDMO Pharmaceutical Product and Services
    Table 128. Creosalus Inc Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 129. Creosalus Inc Recent Developments/Updates
    Table 130. Creosalus Inc Competitive Strengths & Weaknesses
    Table 131. Scinopharm Basic Information, Area Served and Competitors
    Table 132. Scinopharm Major Business
    Table 133. Scinopharm Peptide CDMO Pharmaceutical Product and Services
    Table 134. Scinopharm Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 135. Scinopharm Recent Developments/Updates
    Table 136. Scinopharm Competitive Strengths & Weaknesses
    Table 137. Senn Chemicals Basic Information, Area Served and Competitors
    Table 138. Senn Chemicals Major Business
    Table 139. Senn Chemicals Peptide CDMO Pharmaceutical Product and Services
    Table 140. Senn Chemicals Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 141. Senn Chemicals Recent Developments/Updates
    Table 142. Senn Chemicals Competitive Strengths & Weaknesses
    Table 143. Belyntic Basic Information, Area Served and Competitors
    Table 144. Belyntic Major Business
    Table 145. Belyntic Peptide CDMO Pharmaceutical Product and Services
    Table 146. Belyntic Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 147. Belyntic Recent Developments/Updates
    Table 148. Belyntic Competitive Strengths & Weaknesses
    Table 149. Ferring Pharma Basic Information, Area Served and Competitors
    Table 150. Ferring Pharma Major Business
    Table 151. Ferring Pharma Peptide CDMO Pharmaceutical Product and Services
    Table 152. Ferring Pharma Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 153. Ferring Pharma Recent Developments/Updates
    Table 154. Ferring Pharma Competitive Strengths & Weaknesses
    Table 155. Numaferm Basic Information, Area Served and Competitors
    Table 156. Numaferm Major Business
    Table 157. Numaferm Peptide CDMO Pharmaceutical Product and Services
    Table 158. Numaferm Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 159. Numaferm Recent Developments/Updates
    Table 160. Numaferm Competitive Strengths & Weaknesses
    Table 161. Hybio Pharmaceutical Basic Information, Area Served and Competitors
    Table 162. Hybio Pharmaceutical Major Business
    Table 163. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Product and Services
    Table 164. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 165. Hybio Pharmaceutical Recent Developments/Updates
    Table 166. Hybio Pharmaceutical Competitive Strengths & Weaknesses
    Table 167. Provepharm Life Solutions Basic Information, Area Served and Competitors
    Table 168. Provepharm Life Solutions Major Business
    Table 169. Provepharm Life Solutions Peptide CDMO Pharmaceutical Product and Services
    Table 170. Provepharm Life Solutions Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 171. Provepharm Life Solutions Recent Developments/Updates
    Table 172. Provepharm Life Solutions Competitive Strengths & Weaknesses
    Table 173. Enzene Biosciences Basic Information, Area Served and Competitors
    Table 174. Enzene Biosciences Major Business
    Table 175. Enzene Biosciences Peptide CDMO Pharmaceutical Product and Services
    Table 176. Enzene Biosciences Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 177. Enzene Biosciences Recent Developments/Updates
    Table 178. Piramal Pharma Basic Information, Area Served and Competitors
    Table 179. Piramal Pharma Major Business
    Table 180. Piramal Pharma Peptide CDMO Pharmaceutical Product and Services
    Table 181. Piramal Pharma Peptide CDMO Pharmaceutical Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 182. Global Key Players of Peptide CDMO Pharmaceutical Upstream (Raw Materials)
    Table 183. Peptide CDMO Pharmaceutical Typical Customers
List of Figure
    Figure 1. Peptide CDMO Pharmaceutical Picture
    Figure 2. World Peptide CDMO Pharmaceutical Total Market Size: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Peptide CDMO Pharmaceutical Total Market Size (2018-2029) & (USD Million)
    Figure 4. World Peptide CDMO Pharmaceutical Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
    Figure 5. World Peptide CDMO Pharmaceutical Revenue Market Share by Region (2018-2029), (by Headquarter Location)
    Figure 6. United States Based Company Peptide CDMO Pharmaceutical Revenue (2018-2029) & (USD Million)
    Figure 7. China Based Company Peptide CDMO Pharmaceutical Revenue (2018-2029) & (USD Million)
    Figure 8. Europe Based Company Peptide CDMO Pharmaceutical Revenue (2018-2029) & (USD Million)
    Figure 9. Japan Based Company Peptide CDMO Pharmaceutical Revenue (2018-2029) & (USD Million)
    Figure 10. South Korea Based Company Peptide CDMO Pharmaceutical Revenue (2018-2029) & (USD Million)
    Figure 11. ASEAN Based Company Peptide CDMO Pharmaceutical Revenue (2018-2029) & (USD Million)
    Figure 12. India Based Company Peptide CDMO Pharmaceutical Revenue (2018-2029) & (USD Million)
    Figure 13. Peptide CDMO Pharmaceutical Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Peptide CDMO Pharmaceutical Consumption Value (2018-2029) & (USD Million)
    Figure 16. World Peptide CDMO Pharmaceutical Consumption Value Market Share by Region (2018-2029)
    Figure 17. United States Peptide CDMO Pharmaceutical Consumption Value (2018-2029) & (USD Million)
    Figure 18. China Peptide CDMO Pharmaceutical Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Peptide CDMO Pharmaceutical Consumption Value (2018-2029) & (USD Million)
    Figure 20. Japan Peptide CDMO Pharmaceutical Consumption Value (2018-2029) & (USD Million)
    Figure 21. South Korea Peptide CDMO Pharmaceutical Consumption Value (2018-2029) & (USD Million)
    Figure 22. ASEAN Peptide CDMO Pharmaceutical Consumption Value (2018-2029) & (USD Million)
    Figure 23. India Peptide CDMO Pharmaceutical Consumption Value (2018-2029) & (USD Million)
    Figure 24. Producer Shipments of Peptide CDMO Pharmaceutical by Player Revenue ($MM) and Market Share (%): 2022
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Peptide CDMO Pharmaceutical Markets in 2022
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Peptide CDMO Pharmaceutical Markets in 2022
    Figure 27. United States VS China: Peptide CDMO Pharmaceutical Revenue Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Peptide CDMO Pharmaceutical Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. World Peptide CDMO Pharmaceutical Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Figure 30. World Peptide CDMO Pharmaceutical Market Size Market Share by Type in 2022
    Figure 31. Liquid-phase Peptide Synthesis（LPPS）
    Figure 32. Solid-phase Peptide Synthesis（SPPS）
    Figure 33. Mixed Phase
    Figure 34. World Peptide CDMO Pharmaceutical Market Size Market Share by Type (2018-2029)
    Figure 35. World Peptide CDMO Pharmaceutical Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Figure 36. World Peptide CDMO Pharmaceutical Market Size Market Share by Application in 2022
    Figure 37. Peptide Supplements
    Figure 38. Peptide Vaccines
    Figure 39. Others
    Figure 40. Peptide CDMO Pharmaceutical Industrial Chain
    Figure 41. Methodology
    Figure 42. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Related Reports

Global Peptide CDMO Pharmaceutical Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Peptide CDMO Pharmaceutical Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 29 Mar 2023

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Peptide CDMO Pharmaceutical market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global Peptide CDMO Pharmaceutical Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Peptide CDMO Pharmaceutical Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 10 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Peptide CDMO Pharmaceutical market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Global Peptide CDMO Pharmaceutical Supply, Demand and Key Producers, 2024-2030

Global Peptide CDMO Pharmaceutical Supply, Demand and Key Producers, 2024-2030

date 17 Feb 2024

date Pharma & Healthcare

The global Peptide CDMO Pharmaceutical market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

Product Tags

Peptide CDMO Pharmaceutical

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>